Posted On: 10/08/2014 11:58:46 AM
Post# of 30037
Re: biotechexpert #7804
I think Q1 2016 is probably a safe assumption for the start of MANF clinical trials. But...the excitement comes from guessing how many MANF orphans we'll have by then, and how soon from that point we'll be entering into multiple MANF partnerships!
Q1 2016 also corresponds with the time frame that Lympro revenue will be exploding!!!!
I think realistic thinking concerning time frames is the best policy. But given what will be happening at the beginning of 2016.....it should send waves of excitement backwards in time to say....Q1 2015. I think all that AMBS has going for it will finally dawn on the market in January 2015 and the pps will shoot up. We'll probably up list February 1st, 2015.
With that being said, values should start creeping up slowly from here.
Q1 2016 also corresponds with the time frame that Lympro revenue will be exploding!!!!
I think realistic thinking concerning time frames is the best policy. But given what will be happening at the beginning of 2016.....it should send waves of excitement backwards in time to say....Q1 2015. I think all that AMBS has going for it will finally dawn on the market in January 2015 and the pps will shoot up. We'll probably up list February 1st, 2015.
With that being said, values should start creeping up slowly from here.
(0)
(0)Scroll down for more posts ▼
